Immunotherapy Success Rate for Head and Neck Cancer: What Patients Need to Know in 2025
Head and neck cancer encompasses tumors in the oral cavity, throat, larynx, nasal passages, and increasingly, HPV-associated cancers of the oropharynx. For decades, treatment relied on surgery, radiation, and chemotherapy, but these methods can be challenging for patients and may not always be effective. Immunotherapy, which harnesses the body's immune system to fight cancer, has emerged as a transformative approach for many solid tumors over the past decade. One of the most significant advancements has been the use of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Understanding the success rate of immunotherapy for head and neck cancer can be complex due to its unique mechanism of action and gradual benefits. This patient-friendly article aims to demystify how immunotherapy works, who benefits the most, the findings from clinical trials, and real-world outcomes for individuals living with advanced head and neck cancer.
How Immunotherapy Works in Head and Neck Cancer
The primary immunotherapy drugs for head and neck cancer are PD-1 inhibitors, such as pembrolizumab and nivolumab. These medications block the PD-1 protein on immune cells, preventing cancer cells from using this pathway to evade the immune system. Once PD-1 is inhibited, T-cells can more effectively recognize and attack the tumor.
Immunotherapy does not directly kill cancer cells; instead, it removes barriers that hinder the immune system's ability to defend the body. It's important to note that not all patients respond identically, and some may experience rapid and sustained tumor shrinkage, while others may have stable disease or minimal changes.
Clinical Trial Insights on Success Rates
Clinical trials provide the most reliable data on immunotherapy's effectiveness. The KEYNOTE-048 trial evaluated pembrolizumab as a first-line treatment, while the CheckMate 141 trial studied nivolumab in patients whose cancer had progressed after chemotherapy.
In KEYNOTE-048, pembrolizumab alone demonstrated an overall response rate of approximately 17%, but the results were significantly improved, reaching up to 23%, in patients with high PD-L1 expression (CPS ≥20). When combined with chemotherapy, the response rate increased to 36%, making it an attractive option for patients seeking faster tumor reduction (Burtness et al., 2019). Notably, pembrolizumab improved overall survival, particularly in patients with high PD-L1 expression, and some responses lasted for years rather than months.
The CheckMate 141 trial tested nivolumab in individuals with recurrent or metastatic head and neck cancer who had already received chemotherapy. The overall response rate was approximately 13%, which may seem modest, but the key factor was durability. Many responses lasted over a year, and overall survival improved compared to standard chemotherapy (Ferris et al., 2016). This durability is a hallmark of immunotherapy, as even when response rates are not high, the benefits for responders can be life-changing.
Across various studies, the success rate of immunotherapy, defined as significant and lasting tumor reduction, ranges from 15% to 36%, depending on the patient's tumor type, treatment history, and PD-L1 level. While this percentage may not be as high as in some cancers like melanoma, the quality of responses and long-term survival improvements are substantial.
Success Rates by Patient Subgroup
The likelihood of benefiting from immunotherapy varies among different groups of head and neck cancer patients.
- HPV-Positive (p16-positive) Oropharyngeal Cancer: Patients with HPV-related tumors tend to have better immune recognition and often respond more favorably to immunotherapy. Response rates vary, but these patients typically experience improved overall survival in immunotherapy trials (Cohen et al., 2019).
- High PD-L1 Expression: PD-L1 is a protein found on tumor and immune cells. Tumors with high PD-L1 levels are more likely to respond to pembrolizumab. In KEYNOTE-048, the highest success rates were observed among patients with PD-L1 CPS ≥20, leading to significant improvements in both response and survival.
- Recurrent or Metastatic Disease: Patients with cancer that has returned or spread to distant organs often have limited treatment options. Immunotherapy provides the best chance for long-term disease control, even if initial response rates are modest.
- Patients Previously Treated With Chemotherapy: Immunotherapy remains effective even after chemotherapy has failed, as demonstrated in CheckMate 141. Some patients who had exhausted all standard treatments lived significantly longer due to nivolumab.
Why Success Isn't Solely About Tumor Shrinkage
Immunotherapy differs from chemotherapy in its mechanism of action. While chemotherapy relies on rapid tumor shrinkage to assess treatment success, immunotherapy can produce a slower but more durable effect. Some patients may even experience 'pseudoprogression,' where tumors initially appear larger due to immune cell infiltration before shrinking.
As a result, success is often measured by:
- Overall survival improvement
- Duration of response
- Quality of life
In both major trials, patients receiving immunotherapy experienced longer-lasting responses compared to standard treatments, even when response rates were relatively low.
Duration of Cancer Control with Immunotherapy
For responders, immunotherapy can control head and neck cancer for many months or even years. In some cases, patients remain stable for extended periods after discontinuing the medication. The durability of response is a strong argument for using immunotherapy in eligible patients.
In KEYNOTE-048, nearly 60% of responders were still in response at the two-year mark. In CheckMate 141, some nivolumab responders continued to benefit beyond the three-year follow-up period.
Side Effects: What Patients Should Expect
Immunotherapy is generally well-tolerated compared to chemotherapy, but it can still cause side effects. Most are mild, such as fatigue, skin rash, diarrhea, or low-grade inflammation. However, because immunotherapy activates the immune system, it can sometimes lead to the immune system attacking healthy organs, resulting in thyroid inflammation, colitis, hepatitis, or lung inflammation.
These effects are typically manageable when detected early, and patients are closely monitored during treatment. Prompt reporting of symptoms is crucial.
Discussions to Have with Your Oncologist
Every patient's cancer is unique, and several factors influence the suitability of immunotherapy:
- PD-L1 expression level (CPS score)
- HPV status
- Whether cancer has returned after prior treatment
- The need for rapid tumor shrinkage
- Overall health and ability to tolerate potential side effects
Patients should discuss the benefits and risks, expected success rate for their specific cancer, and whether immunotherapy is available as a standalone treatment or in combination with chemotherapy.
Key Takeaway for Patients
Immunotherapy is not a cure for most head and neck cancer patients, but it has revolutionized treatment expectations. When discussing the immunotherapy success rate in head and neck cancer, it's essential to understand that only a portion of patients experience significant tumor shrinkage. However, those who do benefit often achieve long and meaningful survival improvements that were not possible with older treatments. For the right patient, immunotherapy can offer hope, extended life, and enhanced quality of life.
